Evogene
EVGN
18 hedge funds and large institutions have $52.6M invested in Evogene in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
6% more funds holding
Funds holding: 17 → 18 (+1)
0.08% more ownership
Funds ownership: 2.44% → 2.51% (+0.08%)
4% less capital invested
Capital invested by funds: $54.6M → $52.6M (-$1.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$593K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$555K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$497K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$430K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$663K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$8.71K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$435 |
EVGN Hedge Fund Activity: Q3 2015 in Review
18 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2015, worth a combined $52.6M — down 3.6% from $54.6M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new EVGN positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $593K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $663K sold.
- 18 institutional investors held Evogene (EVGN) as of Q3 2015, up from 17 in Q2 2015.
- Funds reported $52.6M of Evogene stock for Q3 2015, down 3.6% quarter-over-quarter.
- 2 funds opened new Evogene positions in Q3 2015 and 1 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q3 2015 was Goldman Sachs, an estimated $593K added.
- The largest Evogene seller in Q3 2015 was JP Morgan Chase, an estimated $663K sold.
Based on aggregated 13F filings for Q3 2015.